Dear Editor,We would like to share ideas on the publication “A case of morphea following the COVID‐19 mRNA vaccine: on the basis of viral spike proteins.
” Metin and Celepli mentioned that “The pathogenesis of post‐vaccination vasculitis remains unclear. To our knowledge, this is the first report of large vessel vasculitis following by BNT162b2 vaccination…….
” We agree COVID‐19 vaccination might cause adverse effect and the dermatological problem is a possible example. Metin and Celepli reported an interesting case of vaccine recipient presenting with morphea or localized scleroderma. In the current example, however, no definite pathophysiology has been suggested. Atypical immunological responses are frequently cited as a cause of the COVID‐19 vaccine's side effects. It will be beneficial in this scenario if a thorough investigation is conducted. Prior to vaccination, there is also no information on the patient's immunological condition or dermatological health. Morphea in a COVID‐19 immunization recipient could be caused by an underlying disease or a concurrent medial problem. Dengue fever could emerge in a vaccine recipient as an example of a concomitant medical illness.
Dengue fever is also a probable cause of dermatological sclerosis in some people.